Englander Institute for Precision Medicine

Interferon signaling restrains renal cell carcinoma heterogeneity.

TitleInterferon signaling restrains renal cell carcinoma heterogeneity.
Publication TypeJournal Article
Year of Publication2023
AuthorsHolicek P, Fucikova J, Galluzzi L
JournalTrends Cancer
Volume9
Issue11
Pagination871-873
Date Published2023 Nov
ISSN2405-8025
KeywordsCarcinoma, Renal Cell, Humans, Interferon Type I, Kidney Neoplasms, Nucleotidyltransferases, Signal Transduction
Abstract

Type I interferon (IFN) is central to cancer surveillance as it mediates both direct and immune-mediated oncosuppressive effects. A recent study by Perelli et al. suggests that the ability of renal cancer cells to tolerate complex karyotypic alterations elicited by chromosomal instability (CIN), and ultimately acquire full metastatic potential, is also negatively regulated by IFN signaling.

DOI10.1016/j.trecan.2023.08.008
Alternate JournalTrends Cancer
PubMed ID37658022
Grant ListR01 CA271915 / CA / NCI NIH HHS / United States
U54 CA274291 / CA / NCI NIH HHS / United States

Weill Cornell Medicine Englander Institute for Precision Medicine 413 E 69th Street
Belfer Research Building
New York, NY 10021